Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Gains from Sales and Divestitures (2016)

NovaBay Pharmaceuticals (NBY) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $74.0 as the latest value for Q3 2016.

  • On a quarterly basis, Gains from Sales and Divestitures fell 99.95% to $74.0 in Q3 2016 year-over-year; TTM through Sep 2016 was $74.0, a 99.95% decrease, with the full-year FY2015 number at $6000.0, up 50.0% from a year prior.
  • Gains from Sales and Divestitures was $74.0 for Q3 2016 at NovaBay Pharmaceuticals, roughly flat from $74.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $4.9 million in Q3 2013 to a low of -$56000.0 in Q1 2014.
  • A 5-year average of $1.3 million and a median of $64000.0 in 2014 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 101.18% in 2014, then surged 262.5% in 2015.
  • NovaBay Pharmaceuticals' Gains from Sales and Divestitures stood at $28000.0 in 2012, then plummeted by 64.29% to $10000.0 in 2013, then tumbled by 60.0% to $4000.0 in 2014, then skyrocketed by 50.0% to $6000.0 in 2015, then tumbled by 98.77% to $74.0 in 2016.
  • Per Business Quant, the three most recent readings for NBY's Gains from Sales and Divestitures are $74.0 (Q3 2016), $74.0 (Q2 2016), and $72000.0 (Q1 2016).